Hepion Pharmaceuticals, Inc. (HEPA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hepion Pharmaceuticals, Inc. (HEPA) trades at $0.045 with AI Score 47/100 (Grade C). Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for chronic liver diseases. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HEPA: HEPA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HEPA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HEPA: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Hepion Pharmaceuticals, Inc. (HEPA) Healthcare & Pipeline Overview
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of Rencofilstat, a cyclophilin inhibitor for treating non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company focuses on addressing unmet medical needs in liver disease through targeted drug therapies.
What Is the Investment Thesis for HEPA?
Hepion Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's primary value driver is the successful development and commercialization of Rencofilstat for NASH, a large and growing market with limited treatment options. Positive Phase 2 clinical trial results for Rencofilstat would serve as a major catalyst, potentially leading to partnerships or acquisition. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies with more resources. With a market cap of $0.00B and negative P/E ratio, Hepion's valuation is highly dependent on the future success of Rencofilstat. Investors should carefully consider the inherent risks and uncertainties associated with clinical-stage biopharmaceutical companies before investing.
Based on FMP financials and quantitative analysis
HEPA Key Highlights
- Rencofilstat, Hepion's lead drug candidate, has completed Phase 2a clinical trials.
- Hepion is focused on developing treatments for non-alcoholic steatohepatitis (NASH), a significant unmet medical need.
- Rencofilstat targets multiple pathologic pathways involved in the progression of liver disease.
- The company is conducting nonclinical studies to assess Rencofilstat's potential to reduce liver fibrosis and hepatocellular carcinoma tumor burden.
- Rencofilstat has demonstrated antiviral activities towards hepatitis B, C, and D viruses.
Who Are HEPA's Competitors?
HEPA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| COCH Envoy Medical, Inc. | $0.67 | -4.36% | $14.0M | — |
| ENVB Enveric Biosciences, Inc. | $1.27 | -5.22% | — | |
| LIXT Lixte Biotechnology Holdings, Inc. | $7.21 | -6.00% | $89.1M | 56 |
| NIVF NewGenIvf Group Limited | $1.31 | -0.76% | 43 | |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HEPA's Key Strengths?
- Proprietary drug candidate (Rencofilstat) with a novel mechanism of action.
- Clinical-stage development with Phase 2a data.
- Focus on a large and growing market (NASH).
- Experienced management team with expertise in liver disease.
What Are HEPA's Weaknesses?
- Limited financial resources.
- Reliance on a single drug candidate.
- High risk of clinical trial failure.
- Competition from larger pharmaceutical companies.
What Could Drive HEPA Stock Higher?
- Announcement of Phase 2b clinical trial results for Rencofilstat in NASH.
- Advancement of Rencofilstat into Phase 3 clinical trials.
- Potential for partnerships or collaborations with larger pharmaceutical companies.
- Expansion of Rencofilstat into other liver disease indications.
What Are the Key Risks for HEPA?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Rencofilstat.
- Regulatory hurdles in obtaining approval for Rencofilstat.
- Competition from other NASH treatments.
- Limited financial resources.
- Patent expiration for Rencofilstat.
What Are the Growth Opportunities for HEPA?
- Expansion of Rencofilstat into other liver diseases: Hepion has the opportunity to expand the use of Rencofilstat beyond NASH to treat other chronic liver diseases, such as liver fibrosis and hepatocellular carcinoma. Successful clinical trials in these areas could significantly increase the value of Rencofilstat and Hepion Pharmaceuticals.
- Partnerships and collaborations: Hepion can pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of Rencofilstat. These partnerships could provide Hepion with access to additional funding, expertise, and resources, increasing the likelihood of success. The timeline for securing such partnerships is dependent on clinical trial results and market interest.
- Geographic expansion: Hepion can expand its geographic reach by conducting clinical trials and seeking regulatory approval for Rencofilstat in other countries. This would allow Hepion to tap into new markets and increase its revenue potential. The timeline for geographic expansion is dependent on regulatory approvals and market conditions.
- Development of new drug candidates: Hepion can leverage its expertise in liver disease to develop new drug candidates that target different pathways involved in the progression of liver disease. This would diversify Hepion's product pipeline and reduce its reliance on Rencofilstat. The timeline for developing new drug candidates is dependent on research and development efforts and clinical trial results.
- Orphan drug designation: Hepion can seek orphan drug designation for Rencofilstat in certain rare liver diseases. Orphan drug designation provides certain benefits, such as market exclusivity and tax credits, which can incentivize the development of treatments for rare diseases. The timeline for obtaining orphan drug designation is dependent on regulatory review and approval.
What Opportunities Does HEPA Have?
- Partnerships and collaborations with larger pharmaceutical companies.
- Expansion into other liver disease indications.
- Geographic expansion.
- Orphan drug designation.
What Threats Does HEPA Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other NASH treatments.
- Patent expiration.
What Are HEPA's Competitive Advantages?
- Proprietary cyclophilin inhibitor technology with potential for broad application in liver diseases.
- Clinical-stage asset with Phase 2a data demonstrating efficacy and safety.
- Strong intellectual property protection for Rencofilstat.
- Expertise in liver disease biology and drug development.
What Does HEPA Do?
Hepion Pharmaceuticals, Inc., founded in 2013 and headquartered in Edison, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for chronic liver diseases. Originally incorporated as ContraVir Pharmaceuticals, Inc., the company rebranded as Hepion Pharmaceuticals in July 2019 to reflect its sharpened focus on liver disease treatments. The company's lead drug candidate, Rencofilstat, is a cyclophilin inhibitor that has completed Phase 2a clinical trials. Rencofilstat targets multiple pathologic pathways involved in the progression of liver disease, including non-alcoholic steatohepatitis (NASH). Hepion is currently in clinical-phase development for NASH and conducting nonclinical studies to assess Rencofilstat's potential to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Furthermore, Rencofilstat has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. Hepion's research and development efforts are centered on addressing the significant unmet medical needs in the treatment of chronic liver diseases, offering potential therapeutic solutions for patients worldwide.
What Products and Services Does HEPA Offer?
- Develop drug therapy treatment for chronic liver diseases.
- Focus on non-alcoholic steatohepatitis (NASH) treatment.
- Develop Rencofilstat, a cyclophilin inhibitor.
- Conduct clinical trials to evaluate the safety and efficacy of Rencofilstat.
- Conduct nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden.
- Explore antiviral activities towards hepatitis B, C, and D viruses.
How Does HEPA Make Money?
- Develop and license or commercialize novel therapeutics for liver diseases.
- Conduct research and development to identify and validate new drug targets.
- Out-license or partner with larger pharmaceutical companies for late-stage development and commercialization.
- Generate revenue through licensing fees, milestone payments, and royalties.
What Industry Does HEPA Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like Hepion Pharmaceuticals focused on developing innovative therapies for unmet medical needs. The NASH market is a significant area of interest, driven by the increasing prevalence of obesity and diabetes. Competition is intense, with larger pharmaceutical companies and smaller biotechs vying for market share. Success in this industry requires strong scientific expertise, successful clinical trials, and effective regulatory strategies. The industry is subject to stringent regulatory oversight and lengthy development timelines.
Who Are HEPA's Key Customers?
- Patients with chronic liver diseases, particularly NASH.
- Hospitals and clinics that treat liver diseases.
- Pharmaceutical companies seeking to expand their liver disease portfolios.
- Research institutions and universities involved in liver disease research.
Hepion Pharmaceuticals, Inc. (HEPA) Valuation Context
Relative to its peer group, HEPA's quantitative score of 47/100 is roughly in line with the peer average of 57/100.
F-Score 1/9Financial Health
Hepion Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project Hepion Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-472.00.
HEPA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with deep knowledge of the company see value, potentially signaling confidence in future prospects.
- The community is buzzing about upcoming trial results, with many believing positive data could be a major catalyst.
- Hepion seems to be gaining traction in online discussions as a potential acquisition target, fueling speculation and bullish sentiment.
- There's a growing narrative that the market is undervaluing Hepion's pipeline and technology, attracting investors looking for overlooked opportunities.
Bear Case
- Community sentiment is highly reactive to news, making it vulnerable to sharp declines if upcoming trial data disappoints.
- Recent market volatility is making investors risk-averse, potentially limiting interest in smaller biotech companies like Hepion.
- There's concern within the community about the company's cash runway and potential need for future dilution.
- Some analysts are questioning the market potential of Hepion's lead drug candidate, citing competition and regulatory hurdles.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
HEPA Latest News
-
Stocks That Broke Yearly Lows Tuesday Morning
· Aug 6, 2019
HEPA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HEPA.
Price Targets
Wall Street price target analysis for HEPA.
HEPA MoonshotScore
What does this score mean?
The MoonshotScore rates HEPA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kaouthar Lbiati
Unknown
Information on Kaouthar Lbiati's background is not available in the provided data. Without additional context, it is impossible to provide details about their career history, education, or previous roles.
Track Record: Information on Kaouthar Lbiati's track record is not available in the provided data. It is not possible to assess their achievements, strategic decisions, or company milestones under their leadership without more information.
HEPA OTC Market Information
HEPA trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
HEPA Healthcare Stock FAQ
What does the AI Score mean for HEPA?
HEPA holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for chronic liver diseases. Their lead drug candidate, Rencofilstat, targets multiple pathways involved …
What does Hepion Pharmaceuticals, Inc. do?
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of chronic liver diseases. Their lead drug candidate, Rencofilstat, is a cyclophilin inhibitor currently in clinical development for non-alcoholic steatohepatitis (NASH). Rencofilstat targets multiple pathologic pathways involved in the progression of liver disease. The company's strategy involves advancing Rencofilstat through clinical trials and potentially partnering with larger pharmaceutical companies for commercialization.
What are the main risks for HEPA?
Hepion Pharmaceuticals faces several key risks, typical of a clinical-stage biopharmaceutical company. The primary risk is the potential failure of Rencofilstat in clinical trials, which would significantly impact the company's value. Regulatory hurdles and competition from other NASH treatments also pose challenges. Additionally, the company's limited financial resources and reliance on a single drug candidate increase its vulnerability. Investors should carefully consider these risks before investing in HEPA.
How does Hepion Pharmaceuticals, Inc. navigate regulatory approval processes?
Hepion Pharmaceuticals, Inc. navigates regulatory approval processes primarily through adherence to FDA guidelines and regulations. The company conducts rigorous preclinical and clinical trials to demonstrate the safety and efficacy of Rencofilstat. They maintain detailed documentation and communicate regularly with regulatory agencies. Successful navigation of these processes is crucial for obtaining approval for Rencofilstat and bringing it to market, representing a key step in the company's growth strategy.
What revenue streams does Hepion Pharmaceuticals, Inc. have in healthcare?
As a clinical-stage biopharmaceutical company, Hepion Pharmaceuticals, Inc. currently does not have established revenue streams from marketed products. The company's potential revenue streams are contingent upon the successful development and commercialization of Rencofilstat. Future revenue could be generated through licensing agreements, milestone payments, and royalties from sales of Rencofilstat, if approved. Until then, the company relies on funding from investors and potential partnerships to support its operations.
What are the key factors to evaluate for HEPA?
Hepion Pharmaceuticals, Inc. (HEPA) holds an AI score of 47/100 (low). Not financial advice.
How frequently does HEPA data refresh on this page?
HEPA's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HEPA's recent stock price performance?
Hepion Pharmaceuticals, Inc. (HEPA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidate (Rencofilstat) with a novel mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HEPA overvalued or undervalued right now?
Hepion Pharmaceuticals, Inc. (HEPA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data provided.
- AI analysis is pending, limiting the depth of financial analysis.
- CEO background information is not available.